Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MCARH125 |
Synonyms | |
Therapy Description |
MCARH125 are autologous T-cells engineered to express a chimeric antigen receptor (CAR) that targets the B-cell maturation antigen (BCMA; TNFRSF17), which potentially induce cytotoxicity in tumor cells expressing BCMA (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MCARH125 | MCARH-125|MCARH 125 | TNFRSF17 Immune Cell Therapy 25 | MCARH125 are autologous T-cells engineered to express a chimeric antigen receptor (CAR) that targets the B-cell maturation antigen (BCMA; TNFRSF17), which potentially induce cytotoxicity in tumor cells expressing BCMA (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|